Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IPTp (Intermittent Preventive Treatment for malaria in Pregnancy) is a public health intervention and preventive treatment strategy used to reduce the burden of malaria in pregnant women and their newborns. While IPTp is a regimen rather than a single drug, it most commonly refers to the administration of a fixed-dose combination of **sulfadoxine** and **pyrimethamine** (SP) at scheduled intervals during antenatal care visits, regardless of the presence of Plasmodium infection. Sulfadoxine is a sulfonamide that inhibits dihydropteroate synthase (DHPS), and pyrimethamine is an antifolate that inhibits dihydrofolate reductase (DHFR); together, they synergistically disrupt the folate synthesis pathway essential for DNA synthesis in *Plasmodium falciparum*. In clinical research, such as the Washington University School of Medicine-sponsored 'Beleuman Welbodi' trial (NCT03079388) in Sierra Leone, IPTp is evaluated as a core component of anti-infective bundles aimed at improving birth outcomes in malnourished pregnant women.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfadoxine + pyrimethamine (Roche).